Dry eye syndrome (DES) is also known as keratisis sicca and keratoconjunctivitis sicca. Dry eye disease is a common condition that occurs when your tears aren't able to provide adequate lubrication for your eyes. Patients suffering from DES show damage to the ocular surface, instability in the tear film, and visual disturbance. Tear film covers the ocular surface which is made up of three intertwined layers, a superficial lipid layer produced by meibomian glands assist in reducing tear evaporation and uniform tear spreading, middle thick aqueous layer produced from lacrimal glands, and the innermost hydrophilic mucin layer produced from goblet cells of conjunctiva and epithelium of ocular surface. Dry eye syndrome is associated with a long list of causes which can be divided into primary and secondary. Dry eye may develop secondary to inflammatory disease (e.g. vascular, allergic), environmental conditions (e.g. allergens, cigarette smoke, dry climate), hormonal imbalance (e.g. perimenopausal women and patients under hormone replacement therapy), and contact lens wear. Other causes of dry eye are certain diseases, such as rheumatoid arthritis, Sjögren’s syndrome, thyroid disease, and lupus Blepharitis (when eyelids are swollen or red), Entropion (when eyelids turn in), ectropion (eyelids turn outward) and being in smoke, wind or a very dry climate.

Market Dynamics

New dry eye therapies are introduced in the market with several new medications in the pipeline seeking approval. Strong product pipeline offers great market growth opportunity as approval of numerous pipeline products is expected to drive the market growth during the forecast period. For instance, in October 2021, Oyster Point Pharma, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of therapies to address ophthalmic disease, announce the U.S. Food and Drug Administration (FDA) approval for TYRVAYA (varenicline solution) Nasal Spray 0.03 mg, for the treatment of the signs and symptoms of dry eye disease. YRVAYA Nasal Spray is a selective cholinergic agonist delivered twice daily as an aqueous nasal spray into each nostril to activate basal tear production.

Key features of the study:

• This report provides in-depth analysis of the global dry eye syndrome treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global dry eye syndrome treatment market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie Inc., Novartis AG, Bausch Health Companies Inc., Johnson & Johnson, Inc., I-MED Pharma inc., Santen Pharmaceutical Co., Ltd, AFT Pharmaceuticals, Novaliq GmbH, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., Mitotech, SA, Viatris Inc., among other prominent players
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global dry eye syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dry eye syndrome treatment market

Detailed Segmentation:

• Global Dry Eye Syndrome Treatment Market, By Product Type:
  • Cyclosporine
  • Oral Corticosteroid
  • Artificial Tears
  • Omega Supplements
  • Punctual Bags
  • Others
• Global Dry Eye Syndrome Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Supermarket/ Hypermarket
  • Other Stores
  • Online Pharmacies
• Global Dry Eye Syndrome Treatment Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Region/Country
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • AbbVie Inc.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Novartis AG
  • Bausch Health Companies Inc.
  • Johnson & Johnson, Inc.
  • I-MED Pharma inc.
  • Santen Pharmaceutical Co., Ltd
  • AFT Pharmaceuticals
  • Novaliq GmbH
  • Otsuka Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mitotech, SA
  • Viatris Inc.

“*” marked represents similar segmentation in other categories in the respective section.